Avidity
Theresa F. is an experienced professional in regulatory affairs and preclinical drug development, currently serving as Regulatory Affairs Manager at Avidity Biosciences, Inc., and previously holding roles such as Senior Regulatory Affairs Associate and Senior Preclinical Study Coordinator. With a robust background in global regulatory submissions, nonclinical study management, and cross-functional collaboration, Theresa has successfully contributed to securing over USD 30 million in government grant funding. Prior experience includes managing in vivo models at the Ottawa Hospital Research Institute and overseeing animal care and research projects at various institutions. Theresa F. holds a Doctor of Professional Practice in Regulatory and Clinical Research Management and has earned multiple degrees and certifications in regulatory science and project management.
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.